The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy

Supportive Care in Cancer

Volumn 21, Issue 6, 2013, Pages 1655-1663

  Navari, Rudolph M ^a   Nagy, Cindy K ^a   Gray, Sarah E ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Breakthrough nausea and emesis; Chemotherapy; Metoclopramide; Olanzapine

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FOSAPREPITANT; METOCLOPRAMIDE; OLANZAPINE; PALONOSETRON;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BENZODIAZEPINES; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOUBLE-BLIND METHOD; DOXORUBICIN; FEMALE; HUMANS; ISOQUINOLINES; MALE; METOCLOPRAMIDE; MIDDLE AGED; MORPHOLINES; NAUSEA; NEOPLASMS; QUINUCLIDINES; VOMITING;

EID: 84879149213     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1710-6     Document Type: Article

References (39)

1. Bloechl-Daum B, Deuson RR, Panagiotis M et al (2006) Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472-4478
2. Navari RM (2009) Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. Drugs 69:515-533
3. Navari RM (2010) Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncol 6:1073-1084
4. Curran MP, Robinson DM (2009) Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs 69:1853-1858
5. Sankhala KK, Pandya DM, Sarantopoulos J et al (2009) Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant. Expert Opin Drug Metab Toxicol 12:1607-1614
6. Navari RM, Einhorn LH, Loehrer PJ et al (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting. Support Care Canc 15:1285-1291
7. Tan L, Liu J, Liu X et al (2009) Clinical research of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:1-7
8. Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188-195
9. Cohen L, deMoor CA, Eisenberg P et al (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Canc 15:497-503
10. Tina Shih YC, Xu Y, Elting LS (2007) Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer 110:678-685
11. Grunberg SM, Deuson RR, Mavros P et al (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261-2268
12. Hickok JT, Roscoe JA, Morrow GR et al (2003) Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics. Cancer 97:2880-2886
13. Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):232-243
14. Basch E, Prestrud AP, Hesketh PJ et al (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189-4198
15. NCCN (2012) NCCN clinical practice guidelines in oncology. Antiemesis version 1. http://www.nccn.org. Accessed 15 Nov 2012
16. Kris MC (2003) Why do we need another antiemetic? Just ask. J Clin Oncol 21:4077-4080
17. National Cancer Institute (2012) www.cancer.gov/cancertopics/pdq/ supportivecare/nausea/healthprofessional. Accessed 15 Nov 2012
18. Wales J, Sanger L (2001) www.wikipedia.org/wiki/Metoclopramide. Accessed 1 Nov 2012
19. Bymaster FP, Calligaro D, Falcone J et al (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96
20. 6 receptors by olanzapine. Eur J Pharmacol 430:341-349
21. Allison DB, Casey DE (2001) Antipsychotic-associated weight gain: a review of the literature. J Clin Psychiatr 62:22-31
22. Hale AS (1997) Olanzapine. Br J Hosp Med 58:443-445
23. Goldstein LE, Sporn J, Brown S et al (1999) New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 40:438-443
24. Cleeland CS, Mendoza TR, Wang XS et al (2000) Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 89:1634-1646
25. Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study group. J Clin Oncol 21:4112-4119
26. Longo F, Mansuetto G, Lapadula V et al (2012) Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy. Int J Clin Pract 66:753-757
27. Hesketh PJ, Navari RM, Grote T et al (1996) Double blind randomized comparison of the antiemetic efficacy of intravenous dolasetron and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 14:2242-2249
28. Navari RM, Gandara D, Hesketh PJ et al (1995) Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 13:1242-1248
29. Hulstaert F, VanBelle S, Bleiberg H et al (1994) Optimal combination therapy with tropisetron in 445 patients with incomplete control of chemotherapy-induced nausea and vomiting. J Clin Oncol 12:2439-2446
30. The Italian Group for Antiemetic Research (2000) Dexamethasone alone or in combination with ondanseteron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 342:1554-1559
31. Jones JM, Qin R, Bardia A et al (2011) Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy. J Palliat Med 14:810-814
32. Bleicher J, Bhaskara A, Huyck T et al (2008) Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: results from two pilot trials. J Support Oncol 6:27-32
33. Passik SD, Lundberg J, Kirsh K et al (2002) A pilot exploration of the antiemetic activity of olanzapine (Zyprexa) for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manag 23:526-532
34. Pirl WF, Roth AJ (2000) Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psychooncology 9:84-87
35. Jackson WC, Tavernier L (2003) Olanzapine for intractable nausea in palliative care patients. J Palliat Med 6:251-255
36. Srivastava M, Brito-Dellan N, Davis MP et al (2003) Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manag 25:578-582
37. Rudd JA, Ngan MP, Wai MK et al (2006) Antiemetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin. Neurosci Lett 393:79-83
38. Yakabi K, Sadakane C, Noguchi M et al (2010) Reduced ghrelin secretion in the hypothalamus of rats due to cisplatin-induced anorexia. Endocrinology 151:3773-3782
39. Ithimakin S, Runglodvatana K, Nimmannit A et al (2012) Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice. Support Care Canc 20:849-855